Adding brentuximab vedotin to lenalidomide and rituximab improves OS in R/R DLBCL

IF 82.2 1区医学 Q1 ONCOLOGY Nature Reviews Clinical Oncology Pub Date : 2025-01-20 DOI:10.1038/s41571-025-00988-1

David Killock

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

来那度胺和利妥昔单抗联合brentuximab vedotin可改善R/R DLBCL的OS

造血干细胞移植（HSCT）和cd19靶向嵌合抗原受体（CAR） T细胞是治疗复发和/或难治性弥漫性大B细胞淋巴瘤（R/R DLBCL）的潜在治疗方法；然而，许多患者无法接受这些治疗或在这些治疗后进一步复发。来自III期ECHELON-3试验的新数据表明，一种新的结合抗cd30抗体-药物偶联brentuximab vedotin （BV）的联合治疗方案有望治疗此类患者。在ECHELON-3中，230例既往接受过≥2条治疗线且不适合HSCT或CAR - T细胞治疗的R/R DLBCL患者被随机分配（1:1）接受来那度胺和利妥昔单抗加BV或安慰剂。主要终点为总生存期（OS）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.